目的 應(yīng)用Ames試驗(yàn)探討泰格列凈是否具有致突變性。方法 采用標(biāo)準(zhǔn)平板摻入法，應(yīng)用組氨酸營(yíng)養(yǎng)缺陷型鼠傷寒沙門(mén)氏菌TA97、TA98、TA100、TA102和TA1535對(duì)泰格列凈進(jìn)行回復(fù)突變?cè)囼?yàn)。結(jié)果 在31.25～2 000μg/皿劑量范圍內(nèi)，加和不加大鼠肝微粒體酶S9平行條件下測(cè)試，泰格列凈Ames回復(fù)突變?cè)囼?yàn)結(jié)果為陰性。結(jié)論 在本試驗(yàn)條件下，泰格列凈無(wú)致突變性。

Objective To study the mutagenicity of Tianagliflozin in Ames assay. Methods Using the standard plate incorporation assay, the bacterial reverse mutation of Tianagliflozin was tested in the histidine defective strains of salmonella typhimurium TA97, TA98, TA100, TA102, and TA1535. Results In the presence and absence of rat liver microsome S9 mix, the results of assay were negative at the dose within 31.25-2 000 μg/plate. Conclusion The mutagenicity of Tianagliflozin was not observed in the assay.

國(guó)家科技重大新藥創(chuàng)制項(xiàng)目（2015ZX09501004）；天津市科技計(jì)劃項(xiàng)目（16PTGCCX00090）